Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen

References

• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–243.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Novero A, Ravella PM, Chen Y, et al. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3:4.
   PubMedGoogle Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor KB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926.
   PubMed Web of Science ®Google Scholar
• Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019–1026.
   PubMed Web of Science ®Google Scholar
• Horizon Discovery Web site [Internet]. Horizon discovery. Horizon Chalice® Bioinformatics Software. Available from: http://chalice.horizondiscovery.com/chalice-portal/documentation/analyzer/home.jsp
   Google Scholar
• Seganish WM, McElroy WT, Herr RJ, et al. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. Bioorg Med Chem Lett. 2015;25:3203–3207.
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–823.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis–Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem. 1981;115:207–216.
   PubMedGoogle Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362–375.
   PubMed Web of Science ®Google Scholar
• Dong S, Guinn D, Dubovsky JA, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124:3583–3586.
   PubMed Web of Science ®Google Scholar
• Salphati L, Wong H, Belvin M, et al. Pharmacokinetic–pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010;38:1436–1442.
   PubMed Web of Science ®Google Scholar
• Chen CI, Gutierrez M, de Nully Brown P, et al. Antitumor activity of selinexor (kpt-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom’s macroglobulinemia (WM). Paper presented at: 55th Annual Meeting of the American Society of Hematology; 2013 December 7–10; New Orleans, LA. Abstract 1942.
   Google Scholar
• Matzuk MM, McKeown MR, Filippakopoulos P, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150:673–684.
   PubMed Web of Science ®Google Scholar
• Cervantes-Gomez F, Balakrishnan K, Wierda WG, et al. Ex-vivo and in-vitro combination strategies with ibrutinib in chronic lymphocytic leukemia. Cancer Res. 2014;74(19 suppl):Abstract 4769. doi: 10.1158/1538-7445.AM2014-4769
   Web of Science ®Google Scholar
• Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168:765–768.
   PubMed Web of Science ®Google Scholar
• Chen S, Dai Y, Harada H, et al. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007;67:782–791.
   PubMed Web of Science ®Google Scholar
• Kloo B, Nagel D, Pfeifer M, et al. Critical role of PI3K signaling for NF-kB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2011;108:272–277.
   PubMed Web of Science ®Google Scholar
• Campbell V, Thompson R, Villegas V, et al. The potent PI3K-dg, inhibitor IPI-145 exhibits differential activity in diffuse large B-cell lymphoma (DLBCL) cell lines. Paper presented at: 55th Annual Meeting of the American Society of Hematology; 2013 December 7–10; New Orleans, LA. Abstract 1832.
   Google Scholar
• Mathews Griner LA, Guha R, Shinn P, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111:2349–2354.
   PubMed Web of Science ®Google Scholar
• Lim KH, Romero DL, Chaudhary D, et al. IRAK4 kinase as a novel therapeutic target in the ABC subtype of diffuse large B cell lymphoma. Paper presented at: 54th Annual Meeting of the American Society of Hematology; 2012 December 8–11; Atlanta, GA. Abstract 62.
   Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122:1222–1232.
   PubMed Web of Science ®Google Scholar
• Goldstein RL, Yang SN, Taldone T, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. J Clin Invest. 2015;125:4559–4571.
   PubMed Web of Science ®Google Scholar
• Rui L, Drennan AC, Ceribelli M, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2016;113:E7260–E7267.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL, III, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–737.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Popplewell L, Phillips T, et al. Multicenter phase 1b dose-escalation study of ibrutinib and lenalidomide combined with dose-adjusted EPOCH-R in patients with relapsed/refractory DLBCL. Paper presented at: 57th Annual Meeting of the American Society of Hematology; 2015 December 5–8; Orlando (FL). Abstract 1527.
   Google Scholar